Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review Authors: Edward Willow, Aditi Chaudhri, Linda Hasman, Rajbala Thakur, Michael Scott, Robert H Dworkin Published: 2026 ABSTRACT AbstractBackground and ObjectiveDextromethorphan (DXM), widely used as an over-the-counter antitussive in the United States, exhibits psychoactive effects at supratherapeutic levels that overlap with those of classic and dissociative psychedelics. Reported psychoactive effects have generated interest in DXM as a potential therapeutic agent for treatment-resistant psychiatric disorders. Despite this emerging interest, its therapeutic dosing parameters, safety profile, and dose-response characteristics remain inadequately defined. This systematic review evaluates the existing literature on DXM administered for its psychedelic properties, with the aim of examining dose relationship patterns.MethodsThis systematic review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and was preregistered in PROSPERO (CRD420251142239). PubMed, Embase, and the Cochrane Library were searched through August 8, 2025. Eligible studies included randomized controlled trials, cohort studies, case series, and observational studies reporting DXM effects on primary psychedelic outcomes including hallucinatory effects, subjective experiences, or cognitive effects and secondary outcomes focused on tolerability in human participants. Two independent reviewers conducted screening, data extraction, risk-of-bias assessment, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Because of substantial heterogeneity in study designs, samples, and outcomes, findings were synthesized narratively using normalized relative subjective and physiological response scores derived from reported peak effects, effect gradients, and comparative ratings.ResultsOf 297 records identified, eight studies representing four unique samples met inclusion criteria. One was an ascending dose-sequence study (n = 12), two were crossover studies (n = 20; n = 32), and one was a single-dose study (n = 40) (n = 104 total). Doses ranged from 100 to 960 mg. Psychedelic effects were observed at 100 mg, while adverse effects, including nausea, vomiting, motor impairment, and cognitive slowing, became more prominent above 200 mg. Hallucinatory and mystical phenomena intensified at 300 and 400 mg. Risk of bias was generally rated as having some concerns or high risk, and certainty of evidence was low for most primary outcomes and moderate for secondary outcomes.ConclusionAlthough the evidence is too limited to evaluate true dose-response relationships, the literature showed DXM psychedelic effects beginning at 100 mg, with greater phenomenology intensity at 300 and 400 mg. Current findings support only a preliminary descriptive summary of reported psychedelic effects and highlight the need for larger, prospectively designed dose-finding and clinical applicability studies.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40263-026-01305-9. Key Points Dextromethorphan can produce psychedelic-type effects at supratherapeutic doses (> 100 mg).Available studies suggest dose-related increases in both reported psychedelic-type effects and adverse effects, but the evidence remains limited.Current data are insufficient to establish a therapeutic window or clinical relevance, and further dose-response and safety studies are needed. Introduction Dextromethorphan (DXM) is approved as an over-the-counter (OTC) antitussive (cough suppressant) in the United States (US) [1]. DXM is most commonly sold OTC in the US, with adult labelled dosing commonly listed as 10–20 mg every 4 h or 30 mg every 6–8 h, not to exceed 120 mg/day (e.g., Robitussin®) [1]. However, DXM is also consumed recreationally at supratherapeutic doses (> 100 mg) to induce hallucinations, sometimes referred to as “Robotripping” or “Dexing,” in adults and adolescents [2, 3]. The age range of recreational users is highest around 15–19 years old, possibly reflecting accessibility to adolescents; however, adverse effects such as nausea and vomiting may limit long-term repeated high-dose use [2, 4]. In the US, reports of high-dose DXM abuse sharply increased from 2000 to 2006 and then plateaued in data available via the Monitoring the Future (MTF) survey conducted by the National Institute on Drug Abuse (NIDA) [4, 5]. Several websites can be found with specific instructions on the extraction of OTC DXM for psychoactive use [6]. DXM has also recently been utilized in combination with other prescription medications, including bupropion and quinidine for depression, pseudobulbar affective syndrome, amyotrophic lateral sclerosis (ALS), post-operative pain, and pathological laughing/crying disorder [7–11]. Mechanistically, DXM acts on multiple receptors, including N-methyl-D-aspartate (NMDA), α1-adrenergic, serotonin 5-HT1B/1D, sigma-1, α2-adrenergic, and muscarinic acetylcholine receptors, as well as acting as a serotonin-norepinephrine reuptake inhibitor [12–15]. It is speculated that the DXM parent drug and its metabolite dextrophan (DXO) are both responsible for the drug’s psychoactive effects, with DXO more consistently reinforcing self-administration behavior in animals than DXM [16, 17]. However, both DXM and DXO served as a strong substitute for the stimulating effects of phencyclidine (PCP) in rodents [18]. Psychedelic experiences can be defined as a temporary altered state of consciousness characterized by profound changes in perception, thought processes, emotions, and sense of self with often mystical or spiritual impact [19]. Psychedelic compounds that cause acute positive alterations in consciousness, such as mystical-type experiences, have been associated with improved therapeutic outcomes for mood disorders, although the nature of this relationship remains unclear [20]. DXM is known to have psychedelic properties recreationally, but its dose-response relationship is yet to be fully defined. Hallucinations from DXM have been described as sharing features of classic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), and mechanistic NMDA antagonism overlap with atypical psychedelics, such as ketamine and PCP [21–25]. Study participants also reported an increase in impactful mystic experiences, such as intensely meaningful internal and external connection to reality outside regular senses similar to classic and atypical psychedelics [21–23, 26]. Many of these drugs have been examined for the treatment of various psychiatric conditions, and esketamine (Spravato®) has been approved by the Food and Drug Administration (FDA) for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior [27]. Dosing regimen and frequency varies, but often ketamine is administered off label in a calm and secluded environment as the patient undergoes an altered state of consciousness with meaningful emotional, cognitive, and/or spiritual characteristics [28]. Psilocybin-based programs have received Breakthrough Therapy designation for treatment-resistant depression and major depressive disorder, and lysergide d-tartrate (MM120) has received Breakthrough Therapy designation for generalized anxiety disorder [29–31]. The goal of this systematic review is to examine the literature relevant to the psychedelic potential of DXM to begin to discern a dose-response pattern. Methods This review was conducted and reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [32], and methods were preregistered (PROSPERO, CRD420251142239). Research Strategy and Selection Criteria A medical librarian developed and executed comprehensive searches in PubMed, Embase via Ovid, CENTRAL, and Web of Science from database inception through August 8, 2025, with no date restrictions (see Online Resource 3 for full search strategies). Records were imported into Covidence systematic review software for screening and management [33]. Other studies were identified by looking through all the articles that cite the papers included in the review (forward citation searching), reference list checking, and contacting authors or experts. To retrieve all relevant literature, search strategies combined controlled vocabulary and free-text terms, including DXM, cough syrup, NMDA receptor antagonist, hallucinogenic, psychedelic, and other related terms. Eligible studies included randomized controlled trials, cohort studies, observational studies, and case series that examined DXM dosing regimens associated with psychedelic or hallucinogenic effects. Study selection followed the PICOS (participants, intervention, comparison, outcomes, and study design) framework. Study criteria included male or female of any age, with or without psychiatric or medical conditions. The intervention of interest was treatment with DXM with reported dosing. No populations were excluded from this study. Studies without a dose reported were excluded. Comparisons could include any control intervention, placebo, or the absence of a control. Non-English publications and studies without full-text availability were excluded. Case studies, publications without dosing regimen, abstracts, and clinical trials without peer review were excluded from the study as well. Data Screening, Extraction, and Quality Assessment Screening of titles, abstracts, and full texts was performed independently by two reviewers (EW and AC), with discrepancies resolved through consensus or adjudication by a third reviewer. Data extraction included study design, sample characteristics, participant number, dosing parameters, outcome measures, and adverse events. Owing to heterogeneity in study designs and outcomes, findings were synthesized narratively without a meta-analysis. Endpoints of interest were split into primary outcomes and secondary outcomes. Primary outcomes focused on DXM’s psychedelic properties categorized as hallucinations, mysticism or spiritual impact, and cognitive changes. Hallucinations or psychotic features of interest required reporting through standardized rating scales or described at specific doses. Incidental findings or non-standardized rating scale reports were not included. Similarly, cognitive effects evaluated using validated neuropsychological tools and mysticism/spiritual reporting required validated scales for analysis. Secondary outcomes include subjective effect descriptions and safety/tolerability identified as adverse events. Subjective experiences required validated questionnaires or clinician- and patient-reported measures. Risk of bias was calculated using domain-level risk-of-bias assessment, and was done by two independent reviewers (AC and EW) utilizing the Risk of Bias (RoB) 2 tool (Online Resource 1) [34]. This risk-of-bias assessment deviates from what was described in the PROSPERO protocol that described the use of the Cochrane RoB 1. We chose to use RoB 2 over RoB 1 because of the more structured signaling questions and clear overall bias judgement as opposed to the “other bias” domain. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was performed on the primary and secondary endpoints (Online Resource 2). Relative Scaling A normalized relative subjective or physiological response score was estimated from descriptions and comparative data across all the final, available eight studies [21–23, 35–39]. Each primary and secondary outcome was given a relative score by two independent reviewers (EW and AC) based on the quantifiable endpoints within each validated test and across number of patients. These values are inferred from reported peak effects, dose gradients, and comparative ratings specifically to summarize the psychedelic versus adverse effects of DXM. For instance, hallucinations were scored a 4 at DXM 200 mg based on study population reporting “mild visual” and “perceptual effects” at that associated dose [21, 37]. Similarly, hallucination received a score of 4 at 800 mg due to strong dissociative and psychotomimetic symptoms, but not necessarily vivid or structured hallucinations [21, 23, 37]. Subjective experiences were broadly classified as either positive or negative experiences for the sake of overview. Relative scores are ordinal not interval measures, and should not be interpreted as quantitative effect size estimates. The goal of this relative scaling is not meant to provide formal meta-analysis but rather a rudimentary visual ordinal rank overview based on the limited literature available. Results Reviews, Risk-of-Bias, and GRADE Analysis A total of 297 studies were identified for screening. Of those studies, 262 were removed in screening, due to not meeting criteria. Common reasons for removal were as follows: no DXM mentioned in title or abstract, review papers, and case reports. Many of the screened studies were case reports on patients with unique overdosing toxicity profiles with no information of ingestion dose. Thirty-five papers were reviewed in full text, and of those, 27 were filtered out for being conference abstracts only, being case reports, and/or not including DXM alone in the dosing regimen. This left eight full-text studies for inclusion in this review [21–23, 35–39]. Data from four of these eight studies were derived from two other study samples, thus leaving four studies with original data [21, 23, 36, 38]. All eight studies were included in this review since though participants were shared, additional psychoactive effect data were published (Fig. 1). Risk-of-bias analysis showed the majority of studies showed some concerns [21, 23, 35, 37–39], largely due to the lack of discernment of primary versus secondary outcomes and subsequent publications with secondary outcomes utilizing the same small patient population (Online Resource 1). Two manuscripts received high-risk bias scoring based on missing outcome data and selectivity of reported results [22, 36]. GRADE scoring showed low certainty for the majority of primary outcomes and moderate certainty for secondary outcomes (Online Resource 2). Study selection. Template from source: Page et al. [32] Study Designs and Participant Samples All four studies were relatively small, with sample sizes ranging from 12 to 40 participants, with two crossover studies [23, 36] (n = 20 and n = 32, respectively), one single-dose study [38] (n = 40), and one ascending dose-sequence designed study [21] (n = 12) (Table 1). One study focused on healthy individuals [38], two studies focused on healthy individuals who had experience with singular or multiple types of psychedelics [21, 23], and the final study examined patients with painful diabetic neuropathy or postherpetic neuralgia [36]. For studies that provided detailed demographic information [21, 23, 38], participants were predominantly female (41/72, 56.9%), white (32/72, 44.4%), and Asian-American (32/72, 44.4%). For primary psychedelic endpoints, the data came from two populations, and these were demographically primarily healthy, white (29/32, 90.6%), young (mean 27.8), and male (18/32 56.3%) [21, 23]. Table 1Study design and demographic distribution across studiesStudyStudy designDoseSessions; daysTime between sessionsPopulationNo. male (%)Race (% population)Age (mean; range)Carbonaro et al. 2018[23]Crossover multiple sessions400 mgFive sessions total; one with DXM48 hN = 20Healthy9 (45)White: 95% (19/20)AsA: 5% (1/20)28.5 (22–43)Nelson et al. 1997[36]Crossover120–960 mg dailyDaily for 6 weeksNoneN = 3214 with DN18 with PHNUnknownUnknownUnknownPerry et al. 2015[38]Single dose120 mgOne-time doseNoneN = 40Healthy13 (32.5)AsA: 75% (30/40)White: 7.5% (3/40)Latino: 10% (4/40)AfA: 2.5% (1/40)Other: 5% (2/40)26.5 (3.9 SD*)Reissig et al. 2012[21]Ascending dose sequence100–800 mg12 sessions total; up to 8 DXM sessions per tolerance48 hN = 12Healthy9 (75)White: 83% (10/12)AsA: 8.5% (1/12)AfA: 8.5% (1/12)27.5 (20-40)AfA African-American, AsA Asian-American, DN diabetic neuropathy, DXM dextromethorphan, PHN post-herpetic neuralgia*No range available Study design and demographic distribution across studies Carbonaro et al. 2018 [23] N = 20 Healthy White: 95% (19/20) AsA: 5% (1/20) Nelson et al. 1997 [36] N = 32 14 with DN 18 with PHN Perry et al. 2015 [38] N = 40 Healthy AsA: 75% (30/40) White: 7.5% (3/40) Latino: 10% (4/40) AfA: 2.5% (1/40) Other: 5% (2/40) Reissig et al. 2012 [21] N = 12 Healthy White: 83% (10/12) AsA: 8.5% (1/12) AfA: 8.5% (1/12) AfA African-American, AsA Asian-American, DN diabetic neuropathy, DXM dextromethorphan, PHN post-herpetic neuralgia *No range available Dosing Regimen The dosing range and regimens outlined in four different studies are described in Table 1 [21, 23, 36, 38]. DXM dosing ranged from 100 mg to 800 mg, with varied regimens. Two of the four studies involved recording targeted effects after a single high DXM dose (100–800 mg) and then following up with repeated sessions (5 or 12 sessions total) with a different DXM dose, placebo, or psilocybin [21, 23]. There was at least a 48-h period between sessions. The third study examined psychoactive effects of one-time DXM at 120 mg [38]. The fourth study examined a daily dose of DXM 120–960 mg titrated up to the highest tolerated dose for 6 weeks [36]. Gastrointestinal, Cardiovascular, and Motor Effects There were several physiological and psychological effects of DXM that limited dose escalation in the dose-effect studies. Behavioral, gastrointestinal, and motor effects were most limiting in the ascending-dose study (n = 12) [21]. The majority of patients experienced some kind of dose-response–related gastrointestinal side effects, including nausea and/or vomiting. These effects were reported with single doses as low as 100 mg but were significantly more frequent at doses > 300 mg (n = 12) [21]. Vomiting usually occurred 20+ min after ingestion, suggesting a more central mechanism for nausea/vomiting opposed to a direct gastrointestinal irritant [21, 23]. Cardiovascular effects were described in the ascending-dose study (n = 12), with elevation in heart rate and blood pressure as low as 100 mg [21]. These effects were not severe enough to warrant stopping dose escalation or justify stopping the study. Motor and psychomotor impairments were reported in two studies (n = 32 total) [21, 22]. In Reissig et al.’s ascending-dose study of 12 participants, impairments in total balance were seen starting at 100 mg, and impairment in digit-symbol-substitution task (DSST) response time was observed at 300 mg as later reported in Carter et al. [37]. In the 400-mg DXM crossover study by Carbonaro et al. (2018 and 2020) (n = 20), they saw impairments on motor and psychomotor tests including hand–eye coordination and slowed performance at 400 mg; but it is difficult to discern whether this delay was due to cognitive or motor coordination slowing [22, 37]. Interestingly, no effects were seen on the driving simulation performance test at 120 mg in either control measures or response time in the small single-dose study (n = 40) [38]. Thus, doses > 100 mg affect balance and coordination, but not necessarily hindering all psychomotor responses. Subjective Effects and Mysticism There was a wide range of study participant descriptions of their experience with DXM. Subjective experiences were recorded from the ascending dose-sequence study by Reissig et al. (2012) (n = 12) and crossover study by Carbonaro et al. (2018) (n = 20). Subjective descriptions were categorized based on positive experience, negative experience, or somatic symptom based on dose (Table 2). At 100 mg, participants had higher reporting of “good effects” and “arousing/stimulating,” and both reportedly increased with higher doses [21]. At 200–300 mg, participant descriptions became more conflicted, including reporting of “bad effects,” “dislike drug effect,” “nervous/anxiousness,” “confused/disoriented,” “forgetful,” and “unsteady,” while previous positive effects were still present (n = 12). Positive subjective responses seem to become more prominent at 400 mg, with the penultimate dosing including “peace/harmony,” “joyful/happiness,” and “boundless pleasure.” However, this is potentially due to the fact that 400 mg represents a separate study that examined only one dose of DXM (n = 20) [23]. Table 2Subjective experiences and somatic symptomsDosePositive subjective experienceNegative subjective experienceSomatic symptomsStudy100 mgGood effectArousing/stimulatingNot reportedNot reportedReissig et al. 2012 [21]200 mgNot reportedBad effectForgetfulConfused/disorientedNervous/anxiousNausea/vomitingLimbs heavyBlurry visionLightheaded/dizzyUnsteadyShaky/jitteryNumbness/tinglingReissig et al. 2012 [21]300 mgNot reportedDislike drug effectDepressant/sedatingMentally slowed downDifficulty concentratingHot flushedSlurred speechReissig et al. 2012 [21]400 mgHappyaPeace/harmonyaJoyful/happinessaAttitude toward lifeaEuphoriaaEcstasyaBoundless pleasureaSense of awe/amazementaAnxietyaRestless/fidgetyaCarbonaro et al. 2018 [23]Mathai et al. 2023 [39]PenultimatecTalkativeLike drug effectNot reportedRestlessLimb/looseReissig et al. 2012 [21]Max tolerated doseDiabetic neuropathic pain reliefbNot reportedNot reportedNelson et al. 1997 [36]aOne-dose studybDose not specified. Symptom listed in earliest dose observedcPenultimate dose = dose immediately below each participant’s maximum dose administered aka. tolerated dose Subjective experiences and somatic symptoms Good effect Arousing/stimulating Bad effect Forgetful Confused/disoriented Nervous/anxious Nausea/vomiting Limbs heavy Blurry vision Lightheaded/dizzy Unsteady Shaky/jittery Numbness/tingling Dislike drug effect Depressant/sedating Mentally slowed down Difficulty concentrating Hot flushed Slurred speech Happya Peace/harmonya Joyful/happinessa Attitude toward lifea Euphoriaa Ecstasya Boundless pleasurea Sense of awe/amazementa Carbonaro et al. 2018 [23] Mathai et al. 2023 [39] Talkative Like drug effect Restless Limb/loose aOne-dose study bDose not specified. Symptom listed in earliest dose observed cPenultimate dose = dose immediately below each participant’s maximum dose administered aka. tolerated dose Interestingly, DXM was consistent in not enhancing positive social effects such as emotional closeness with the guide or increased awareness of interpersonal relationships [35]. Carbonaro et al. in 2020 also found that many of the positive subjective effects of 400 mg DXM remained significant after 1 week in a follow-up examination; however, this study was a multi-session design, with multiple doses of psilocybin also examined, so it is difficult to discern whether DXM or psilocybin sessions played a more significant role in this persisting effect. One study also reported a significant decrease in self-reported diabetic peripheral neuropathy pain with daily DXM for 6 weeks; however, no specific dose was listed as it was a dose-response study with titration to an individual’s tolerance level [36]. Subjective effects related to mysticism and spirituality were specifically reported in four studies [21, 23, 35, 39] with two unique study populations in an ascending dose-sequence study (n = 12) and a multiple crossover sessions study (n = 20) (Table 3) [21, 23]. DXM showed increases on a mysticism scale and other subjective reports of altered states of consciousness. Increases in mysticism were seen as low as the 100-mg DXM dose (n = 12), but doses 300 mg and greater showed the largest impact, with increased reports of interpretation, sense of sacredness, and transcendence of time/space (n = 32). This was found to be psychologically challenging but impactful, personally meaningful, and spiritually significant [39]. Table 3Hallucinogenic, mysticism, and cognitive effects by doseDoseHallucinationsMysticism/state of consciousnessCognitive effectsStudy100 mgIncreasedIntrovertiveFree recall memoryReissig et al. 2012 [21]200 mgSomaesthesiaCognitiveExtrovertiveInterpretationTotalWord recognitionReissig et al. 2012 [21]300 mgAffectPerceptionVolitionInternal and external unitySense of sacrednessIntuitive knowledgeTranscendence time/spaceDeeply-felt positive moodIneffabilityDivided attentionWorking memoryReissig et al. 2012 [21]400 mgVisual effectsaElementary imageryComplex imageryaMovement within visionsaAudiovisual synesthesiaaChanged meaning of preceptsaChallenging experience of hallucination: physical distress, fear, insanity, isolation, and deathaDistance from normal realityaSense of pure being and pure awarenessaFusion of personal self into larger wholeaSense of reverence/sacrednessaPsychological insightaPersonally meaningfulaSpiritually significantaPsychologically challengingaPsychologically insightfulaEpisodic memoryaVisual processingaBarrett et al. 2018 [22]Carbonaro et al. 2018 [23]Carbonaro et al. 2020 [35]Mathai et al. 2023 [39]PenultimatebLiked the overall experienceNot reportedNot reportedReissig et al. 2012 [21]aOne-dose studybPenultimate dose = dose immediately below each participant’s maximum dose administered aka. tolerated dose Hallucinogenic, mysticism, and cognitive effects by dose Somaesthesia Cognitive Extrovertive Interpretation Total Affect Perception Volition Internal and external unity Sense of sacredness Intuitive knowledge Transcendence time/space Deeply-felt positive mood Ineffability Divided attention Working memory Visual effectsa Elementary imagery Complex imagerya Movement within visionsa Audiovisual synesthesiaa Changed meaning of preceptsa Challenging experience of hallucination: physical distress, fear, insanity, isolation, and deatha Distance from normal realitya Sense of pure being and pure awarenessa Fusion of personal self into larger wholea Sense of reverence/sacrednessa Psychological insighta Personally meaningfula Spiritually significanta Psychologically challenginga Psychologically insightfula Episodic memorya Visual processinga Barrett et al. 2018 [22] Carbonaro et al. 2018 [23] Carbonaro et al. 2020 [35] Mathai et al. 2023 [39] aOne-dose study bPenultimate dose = dose immediately below each participant’s maximum dose administered aka. tolerated dose Hallucinogenic Effect Visual hallucinations were commonly found across studies (Table 3). Three studies specifically report these findings utilizing the Hallucinogen Rating Scale [21, 23, 35], with two of those studies, ascending-dose study (n = 12) and crossover study (n = 20), being unique populations [21, 23]. DXM showed significant dose-related increases in all hallucinogen subscales including perceptual, mood, and cognitive changes. This dose effect was seen starting at 100 mg with significant increases in somaesthesia, affect, and perception occurring at 200–300 mg (n = 12). At 400 mg of DXM, participants report more complex and profound hallucinations, with elementary and complex imagery, movements within visions, audiovisual synthesis, and challenging emotional experiences (n = 32) [23, 35]. Cognitive Effects DXM significantly impaired cognition in a dose-dependent manner [22, 37]. Cognitive effects that were examined included attention, memory, and visual processing. In a dose-response study, a decrease in free recall memory was seen at 100 mg, word recognition at 200 mg, and working memory and divided attention at 300 mg [37]. A single-dose study showed decreased episodic memory and visual processing at 400 mg [22]. Relative Scaling Comparison Relative scaling of primary outcomes shows higher psychedelic effects around 400 mg, which are overtaken by adverse events/negative experiences at higher doses (Fig. 2) [21–23, 35–39]. Secondary adverse outcomes continued to rise progressively with no obvious plateau observed at 800 mg. This rudimentary analysis is only meant to serve as an ordinal visual summary of reported effects of DXM in comparison to adverse events, and as such is heavily impacted by the limited literature. This is not a true dose-response curve and should not be interpreted as such. Preliminary ordinal visual summary of reported psychedelic-type and adverse effects of DXM. Relative intensities are ordinal values derived from normalized subjective or physiological responses across studies [21–23, 35–37]. Values were extrapolated from reported peak dose effects and comparative ratings. Cardiac effects include increase in heart rate and blood pressure. Of note, this is a relative scale of intensity that was extrapolated roughly across studies. This is a preliminary analysis based on very limited data and does not represent a true dose-response assessment. DXM dextromethorphan Discussion Limitations Overall, there are very few rigorous studies examining DXM as a psychedelic. Only four studies contained dose-specific information regarding DXM psychedelic use: an ascending dose-sequence, healthy volunteer study (n = 12; 100–800 mg) [21], a double-blind crossover multi-session study in healthy participants with prior hallucinogen exposure (n = 20; 400 mg DXM sessions) [23], a crossover titration trial in painful diabetic neuropathy or postherpetic neuralgia (n = 32; 120–960 mg/day over 6 weeks) [36], and a single-dose, healthy volunteer, driving sobriety study (n = 40; 120 mg) [38]. Four additional articles reported additional analyses utilizing data from the original studies [22, 35, 37, 39]. Thus, the apparent evidence base of eight articles reflects only four unique participant samples. Major concerns highlighted by the RoB 2 and GRADE analyses are as follows: poorly defined primary and secondary outcomes across studies, multiple publications utilizing the same participant population, missing data due to adverse effects, lack of generalizability due to homogeneity of participant population, and lack of long-term endpoint assessment. These factors in combination make the limited amount of literature generally at moderate risk of bias with low certainty of evidence for primary endpoints. One of the largest sources of bias comes from the poorly defined primary and secondary outcomes amongst studies. This lack of clearly defined outcomes and splitting findings into subsequent publications puts the literature at increased risk of selective outcome reporting bias. Without predefined primary outcomes, it becomes difficult to determine whether reported findings reflect the original study objectives or were emphasized post hoc based on statistical significance or perceived impact. This ambiguity limits interpretability and increases the possibility that less favorable findings were underreported. Another concern is the lack of generalizability of these works due to the majority of study population being young healthy volunteers. Detailed demographic characteristics were available only for the subset of participants in studies that reported these data, and therefore demographic interpretation should not be generalized across all articles. Of note, the two unique populations primarily focused on the primary psychedelic outcomes of DXM were primarily healthy, young, white, males, thus, furthering the lack of generalizability. This homogeneity in participants not only limits our understanding of DXM use as a psychedelic but also does not provide any therapeutic insight for patients suffering from psychiatric disorders. Across studies, there are also no endpoints centered around how psychedelic experience might impact psychiatric disease, further limiting the generalization of this work. Further studies need to examine a more diverse population for generalizability and to better understand the psychiatric therapeutic potential of DXM. Missing data also heavily biases these studies. The apparent decline or plateau in psychedelic effects after 400 mg should be interpreted cautiously because it may reflect study design differences and participant dropout rather than a true pharmacological ceiling. Participants unable to tolerate lower or intermediate doses may not have contributed data at higher doses, which is particularly relevant given this small sample size. It is also likely this peak of psychedelic effects is due to the majority of the studies only use a single 400-mg dose, often intentional based on initial tolerability studies [23, 37]. Understanding this bias is important when drawing conclusions based on these studies, and particularly for the interpretation of Fig. 2. Larger studies are needed to discern whether the peak psychedelic effects seen at 400 mg are due to maximum effect or bias due to patient intolerability. Long-term benefits from multiple sessions are also unclear based on study design. Studies that measured long-term changes in spirituality/mysticism received DXM across multiple sessions alongside other substances, psilocybin and triazolam; therefore, we are unable to discern the substance impacting the long-term changes. Because these findings come from a small crossover sample with repeated exposure to multiple psychoactive comparators, persistent psychological or mystical effects should be attributed cautiously and should not be interpreted as DXM-specific therapeutic effects. Understanding the therapeutic potential of DXM as a psychedelic requires future studies focused on short-term and long-term therapy benefit. Future research should first establish the dose-related effects of DXM in larger, well-characterized healthy samples using prospectively defined outcomes and rigorous assessment of subjective, cognitive, and physiological effects. Only after these foundational studies are completed should indication-specific therapeutic trials be undertaken in clinical populations. Such studies will be necessary because the dose range associated with acceptable tolerability and potentially relevant psychoactive effects may differ across conditions, such as chronic pain syndromes and depressive disorders. At present, the clinical relevance of DXM’s psychedelic effects has not been established, and the available literature is insufficient to define a therapeutic dose range or infer clinical utility. The present review is intended to summarize the limited existing evidence, identify knowledge gaps, and inform the design of future pharmacological and clinical studies. DXM as a Psychedelic Although DXM dosing > 100 mg per day is considered supratherapeutic for its use as an antitussive, it is not unusual to see these dosages prescribed to reduce nasal drip in clinical practice. Across the available human studies, reported psychedelic-type effects of DXM, including hallucinations and mystical experiences, were observed with single doses as low as 100 mg, but these dose-level interpretations rely heavily on small samples and different study designs. The 100–300-mg dose gradient derives mainly from the ascending dose-sequence study by Reissig et al. (n = 12), whereas much of the 400-mg subjective and mystical-effect literature derives from Carbonaro et al. and related secondary analyses of the same crossover sample (n = 20). The 120-mg single-dose study by Perry et al. (n = 40) contributes more directly to driving/sobriety and tolerability interpretation than to high-dose psychedelic phenomenology, and the Nelson et al. titration trial (n = 32) was conducted in neuropathic pain rather than psychedelic-use conditions [21–23, 35–39]. Participants describe these effects as generally positive and “good experiences.” The psychedelic effects increased in a dose-related pattern with significant changes in state of consciousness, psychological and personal insight, and spirituality with higher single doses of 300–400 mg. As psychedelic effects increased with dose, so too did the side effects. Nausea, vomiting, unsteadiness, loss of balance/coordination, and mental slowing all increased after 200 mg. Impactful cognitive effects such as memory and attention also started to manifest in the 200–300 mg range. These findings may help guide future dose-finding studies, but current evidence is insufficient to identify an optimal therapeutic dose. The hallucinations and mysticism scales were higher with 400 mg compared to 300 mg, with more complex visual and psychological impacts. However, it is possible that differences were potentially due to different research methods among the studies. For example, Carbonaro et al. (2018) examined a single dose of 400 mg DXM, and participants associated the effects as similar to classic psychedelics, such as psilocybin and LSD, thus potentially making it appear as a control condition. However, DXM psychedelic effects seem to have the properties of both classic psychedelics and dissociative psychedelics, such as ketamine. We see similar subjective descriptions of DXM to those of classic psychedelics, such as “euphoria” and “ecstasy,” alongside visual and auditory changes, as well as effects similar to dissociative psychedelics such as “transcendence time/space” and “ineffability.” This overlap in subjective effects coincides with DXM’s mechanistic properties, including its serotonergic and NMDA receptor effects. Preclinical studies in rats and rhesus monkeys support pharmacological and behavioral overlap with NMDA antagonist/PCP-like discriminative stimulus or reinforcement paradigms, but these animal data do not demonstrate hallucinations, mystical experience, psychological insight, or other human subjective phenomenology [16–18]. Both classic and dissociative psychedelics are being studied for treatment-resistant psychiatric disorders, including mood, anxiety, and substance use disorders [40–43]. Future studies would benefit not only from exploring the clinical relevance of DXM but also comparing the positive and adverse effect profile of DXM with other psychedelics of interest, such as psilocybin and ketamine. Comparison across psychedelics in multiple populations will allow clinicians to utilize the most effective therapeutic regimen for specific individuals. Conclusions Available studies suggest that DXM can produce psychedelic effects at supratherapeutic doses, but the current evidence base is too limited and heterogeneous to support conclusions regarding an optimal dose, therapeutic window, or clinically meaningful dose–effect relationship. DXM occupies a unique position at the intersection of classic and dissociative psychedelics, producing profound alterations in perception, cognition, mystical, and other non-ordinary states of consciousness at clinically achievable doses. Although preliminary findings suggest that DXM can produce dose-related psychedelic-type effects, the clinical relevance of these effects has not been established and the available evidence is insufficient to define an indication-specific therapeutic dose range. Additional rigorous dose-finding, safety, and therapeutic studies will be essential if DXM’s psychedelic properties are to transition from recreational use to a validated therapeutic. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 258 kb) Supplementary file2 (PDF 170 kb) Supplementary file3 (PDF 169 kb) Funding Financial support was provided by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public–private partnership with the US Food and Drug Administration (FDA), which has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, philanthropy, royalties, and other sources. The views expressed in this article are those of the authors, and no official endorsement by the FDA or the pharmaceutical and device companies that provided unrestricted grants to support ACTTION should be inferred. Declarations Conflict of interest Robert H. Dworkin, PhD, since January 1, 2023, has received research grants and contracts from the US FDA and the US National Institutes of Health, and compensation for serving on advisory boards or consulting on clinical trial methods from Aditum, Akigai, Allay, AM-Pharma, Beckley, Biogen, Biohaven, Biosplice, Bsense, Cardialen, Centrexion, Chiesi, Clexio, Coalition for Aligning Sciences, Collegium, CombiGene, Confo, Contineum, Eccogene, Editas, Eli Lilly, Emmes, Epizon, Ethismos (equity), Eurofarma, Exicure, GlaxoSmithKline, Glenmark, JCARE, JucaBio, Kriya, Latigo, Mainstay, Maxona, Merck, Mind Medicine (also equity), Nocicera, Noema, Orion, Q-State, Regenacy, Rho, Salvia, Sangamo, Scilex, Semnur, SIMR Biotech, SiteOne, Sparian, SPM Therapeutics, SPRIM Health, Tiefenbacher, Validae, Vertanical, Ventus, Vertex, Viscera, and WCG. All other authors have no conflicts of interest relevant to the article to declare. Ethics approval Not applicable. This study did not involve human participants, animals, or identifiable personal data, and therefore did not require institutional ethics committee review or approval. Consent to participate Not applicable. No human participants were involved in this study. Consent to publish Not applicable. No human participants were involved in this study. Availability of data and material The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Code availability Not applicable. No custom code or software was used in the preparation of this study. Author contributions EW, AC, LH, and RD contributed to the study conception and design. EW, AC, and LH performed the research and collected the data. EW, AC, MS, and RD analyzed and interpreted the data. EW drafted the initial manuscript, and AC, MS, RT, and RD critically revised the manuscript for important intellectual content. All authors have read and approved the final version, and agree to be accountable for the work. References Associated Data Supplementary Materials Supplementary file1 (PDF 258 kb) Supplementary file2 (PDF 170 kb) Supplementary file3 (PDF 169 kb)